We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-5.2%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$642M
AUM Growth
-$8.55M
Cap. Flow
+$84.4M
Cap. Flow %
13.15%
Top 10 Hldgs %
47.56%
Holding
90
New
25
Increased
18
Reduced
19
Closed
18

Top Buys

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$30M
2
UTHR icon
United Therapeutics
UTHR
+$20.1M
3
FLXN
Flexion Therapeutics, Inc.
FLXN
+$13M
4
EPIX
ESSA Pharma
EPIX
+$10M
5
ORGO icon
Organogenesis Holdings
ORGO
+$9.94M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$18.7M
2
SKIN icon
SkinHealth Systems
SKIN
+$16.1M
3
BCAB icon
BioAtla
BCAB
+$10.9M
4
NVCR icon
NovoCure
NVCR
+$10.8M
5
ITMR
Itamar Medical Ltd. American Depository Shares
ITMR
+$7.74M

Sector Composition

Rank Sector Weight
1 Healthcare 91.89%
2 Financials 1.01%
3 Consumer Staples 0.82%
4 Real Estate 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CORT icon
51
Corcept Therapeutics
CORT
$11.8B
$3.05M 0.48%
+155,000
New +$3.24M
ARYD
52
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$3.02M 0.47%
300,000
– –
CDMO
53
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$2.91M 0.45%
+135,000
New +$3.26M
DYN icon
54
Dyne Therapeutics
DYN
$4.92B
$2.9M 0.45%
178,360
– –
ZGNX
55
DELISTED
Zogenix, Inc.
ZGNX
$2.6M 0.4%
+171,000
New +$2.67M
AXGN icon
56
Axogen
AXGN
$2.43B
$2.5M 0.39%
158,140
– –
LYRA
57
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.97M 0.31%
4,312
+650
+18% +$246K
CELC icon
58
Celcuity
CELC
$4.59B
$1.51M 0.23%
83,688
-81,136
-49% -$1.72M
EIGR
59
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.43M 0.22%
7,117
– –
BVS icon
60
Bioventus
BVS
$948M
$1.34M 0.21%
+94,602
New +$1.46M
CTMX icon
61
CytomX Therapeutics
CTMX
$727M
$1.33M 0.21%
+261,050
New +$1.4M
ATXS
62
DELISTED
Astria Therapeutics
ATXS
$994K 0.15%
112,499
-16,668
-13% -$160K
EDIT icon
63
Editas Medicine
EDIT
$480M
$965K 0.15%
23,500
-72,100
-75% -$3.95M
NGM
64
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$862K 0.13%
+41,000
New +$903K
PRCT icon
65
Procept Biorobotics
PRCT
$1.05B
$763K 0.12%
+20,000
New +$768K
CUTR
66
DELISTED
Cutera, Inc.
CUTR
$675K 0.11%
14,480
-88,500
-86% -$4.37M
BEAM icon
67
Beam Therapeutics
BEAM
$2.86B
$670K 0.1%
7,700
-14,400
-65% -$1.45M
RFL icon
68
Rafael Holdings
RFL
$104M
$668K 0.1%
22,046
-15,210
-41% -$698K
GLUE icon
69
Monte Rosa Therapeutics
GLUE
$1.35B
$557K 0.09%
25,000
-50,000
-67% -$1.43M
EWTX icon
70
Edgewise Therapeutics
EWTX
$4.84B
$520K 0.08%
31,300
– –
DNTH icon
71
Dianthus Therapeutics
DNTH
$6.19B
– –
-5,625
Closed -$880K
DXCM icon
72
DexCom
DXCM
$31.3B
– –
-23,536
Closed -$2.51M
ESTA icon
73
Establishment Labs
ESTA
$2.63B
– –
-26,568
Closed -$2.32M
GH icon
74
Guardant Health
GH
$21.4B
– –
-17,500
Closed -$2.17M
DMRA
75
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.89B
– –
-21,526
Closed -$2.72M
1 2
3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Soleus Capital Management held 90 positions worth $642M, down 1.3% from $650M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Soleus Capital Management deployed $84.4M of net new capital in Q3 2021, opening 25 new positions and adding to 18 existing holdings. Its largest new stake was DICE Therapeutics, Inc. Common Stock: 879,903 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $18.7M trimmed.

  • Soleus Capital Management's largest Q3 2021 buy was DICE Therapeutics, Inc. Common Stock: 879,903 shares worth $28.8M.
  • Soleus Capital Management added most to ESSA Pharma in Q3 2021, an estimated $10M increase.
  • Soleus Capital Management's biggest Q3 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $18.7M.
  • Soleus Capital Management fully exited MiMedx Group in Q3 2021, selling an estimated $4.03M.
  • Soleus Capital Management's ten largest holdings make up 48% of its $642M portfolio in Q3 2021.
  • Soleus Capital Management opened 25 new positions and closed 18 in Q3 2021.
  • Soleus Capital Management's portfolio value fell 1.3% quarter-over-quarter to $642M.

Based on Soleus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.